Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Afferent Pharmaceuticals

http://www.afferentpharma.com/

Latest From Afferent Pharmaceuticals

Korea’s Key Words For 2023: Regulatory Innovation, Digital Healthcare

The Pink Sheet’s roundup of key regulatory issues in Korea for 2022 and outlook for this year.

South Korea Pink Sheet Perspectives

Will The Dark Tunnel For Korean Biopharmas End In 2023?

Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.

Commercial South Korea

Finance Watch: $1.32bn In New Biopharma VC Financings As Year-End Approaches

Private Company Edition: In recent weeks, 19 companies disclosed venture capital funding of $20m or more, including FogPharma with a $178m series D round and Apogee’s $169m launch. Also, Avalon BioVentures spun out of Avalon Ventures with a $135m fund.

Financing Innovation

Banner Year For Novo Nordisk At The 18th Annual Scrip Awards

AstraZeneca and Moderna also shone as the pharma, biotech and allied industries came together in London on 30 November to celebrate a year of exceptional achievement at the 18th Annual Scrip Awards, hosted by the actor, comedian and presenter Stephen Mangan.

Commercial Companies
See All

Company Information

  • Industry
  • Medical Devices
UsernamePublicRestriction

Register